HABA Laboratories, Inc. (4925) AI Stock Analysis

• Market Cap: ¥6.23B
• Dividend Yield: 2.43%
• Average Volume (3M): 973.00
• Price to Earnings (P/E): 10.8
• Beta (1Y): 0.26
• Revenue Growth: -2.13%
• EPS Growth: N/A
• Country: JP
• Employees: 631
• Sector: Consumer Defensive
• Sector Strength: 55
• Industry: Household & Personal Products
• EPS (TTM): 94.05
• Shares Outstanding: 3,935,000
• 10 Day Avg. Volume: 1,440
• 30 Day Avg. Volume: 973
• PEG Ratio: -0.08
• Price to Book (P/B): 0.82
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -37.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 61 Neutral
• Price Target: ¥1,815.00 ▲(10.87%Upside)

HABA Laboratories' overall stock score reflects a mix of strengths and challenges. The company's solid financial stability, as indicated by its strong balance sheet and improving cash flow, is a significant positive factor. However, the company faces challenges with revenue growth and profitability, impacting its income statement negatively. Technical analysis suggests a neutral market position, while the valuation presents an attractive opportunity due to a low P/E ratio and reasonable dividend yield.

HABA Laboratories, Inc. Business Overview & Revenue Model

Company Description

HABA Laboratories, Inc. (4925) is a Japan-based company that operates in the personal care sector. The company focuses on the development, manufacturing, and marketing of health and beauty-related products. Its core products include skincare items, cosmetics, and health supplements, which are designed to cater to a wide range of consumer needs, emphasizing the use of natural and safe ingredients.

How the Company Makes Money

HABA Laboratories, Inc. generates revenue primarily through the sale of its skincare, cosmetics, and health supplement products. The company's revenue model is based on direct sales through its retail outlets, online platforms, and distribution through various retail partners. Significant revenue streams include both domestic and international sales, leveraging brand recognition and quality to appeal to a broad customer base. Additionally, HABA Laboratories may engage in strategic partnerships with other companies in the beauty and health industries, further boosting its market presence and contributing to its earnings.

HABA Laboratories, Inc. Financial Statement Overview

Summary

HABA Laboratories has a mixed financial performance. The income statement is pressured by declining revenue and inconsistent profitability. However, the balance sheet is strong with low leverage and solid equity. Cash flow is improving but has been historically volatile. Overall, the company shows financial stability but needs to address profitability and growth concerns.

Income Statement

HABA Laboratories has faced challenges with revenue growth, showing an overall declining trend from the 2020 peak. The gross profit margin remains robust, suggesting efficient cost management, but net income has fluctuated significantly, impacting net profit margins negatively in recent years. The EBIT and EBITDA margins have been erratic, reflecting operational challenges and inconsistent profitability.

Balance Sheet

The balance sheet shows strong equity with a favorable equity ratio, indicating financial stability. The debt-to-equity ratio is low, reducing leverage risks. However, the return on equity is unstable due to fluctuating net income. Overall, the company maintains a solid asset base with a strong equity cushion.

Cash Flow

Cash flow analysis reveals improving operating cash flow in the most recent period, which is a positive sign. Yet, the company has struggled with free cash flow growth, and previous periods showed volatility. The operating cash flow to net income ratio indicates better cash generation relative to profits recently, but historical instability remains a concern.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	12.30B	12.06B	12.32B	12.04B	12.91B	14.31B
Gross Profit	8.32B	7.99B	8.03B	8.17B	8.79B	10.20B
EBITDA	-537.20M	811.56M	-1.31B	17.05M	448.30M	960.14M
Net Income	-986.62M	576.57M	-2.12B	-707.87M	-269.03M	216.42M
Balance Sheet
Total Assets	12.20B	12.34B	12.43B	14.66B	15.69B	17.44B
Cash, Cash Equivalents and Short-Term Investments	4.01B	4.74B	3.96B	4.82B	5.65B	5.66B
Total Debt	2.11B	1.82B	2.36B	2.03B	2.56B	3.92B
Total Liabilities	3.62B	3.42B	3.92B	3.88B	4.05B	5.40B
Stockholders Equity	8.57B	8.93B	8.51B	10.77B	11.64B	12.04B
Cash Flow
Free Cash Flow	0.00	1.48B	-1.02B	-232.69M	1.53B	-346.95M
Operating Cash Flow	0.00	1.62B	-587.92M	55.96M	1.71B	534.71M
Investing Cash Flow	0.00	-147.18M	-441.79M	-214.40M	-216.49M	-925.08M
Financing Cash Flow	0.00	-689.49M	171.06M	-676.32M	-1.51B	825.38M

HABA Laboratories, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1637.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4925, the sentiment is Negative. The current price of 1637 is below the 20-day moving average (MA) of 1689.45, below the 50-day MA of 1715.34, and below the 200-day MA of 1738.97, indicating a bearish trend. The MACD of -19.25 indicates Positive momentum. The RSI at 24.11 is Positive, neither overbought nor oversold. The STOCH value of 2.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4925.

HABA Laboratories, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4936	69 Neutral	¥11.43B	55.71		2.11%	4.75%	-83.63%
4934	69 Neutral	¥7.83B	10.65		―	-17.95%	―
4932	68 Neutral	¥10.82B	15.19		6.10%	12.45%	-3.65%
Sector *	65 Neutral	$27.33B	15.36	-4.01%	3.14%	1.00%	1.98%
4925	61 Neutral	¥6.23B	10.81		2.43%	-2.13%	―
4929	52 Neutral	¥6.02B	147.32		1.60%	-7.66%	―
4926	45 Neutral	¥4.82B	35.38		1.78%	0.10%	-239.09%